NovoCure, a commercial-stage oncology company developing a proprietary therapy for solid tumors, reported Tuesday preliminary operating statistics for Q4 and full year 2016, posting year-over-year increases in active patients on Optune therapy and prescriptions received.
Optune is a novel therapy for newly diagnosed adult patients with glioblastoma. It is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of the brain where the glioblastoma tumor is located.
The company said that there were 1,091 active patients on Optune therapy on Dec. 31, an increase of 80% versus a year ago. Of the active patients, 835 were in the U.S. and 256 were in Novocure’s EMEA markets.
In Q4, 706 prescriptions were received, an increase of 27% versus in the same quarter in 2015. 544 of the prescriptions were received in the U.S. and 162 were received outside of the U.S., primarily in Europe.